You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
迪瑞醫療(300396.SZ):新增血細胞相關CNAS參考實驗室認可資格
格隆匯 09-22 16:44

格隆匯 9 月 22日丨迪瑞醫療(300396.SZ)公佈,公司在前期獲得中國合格評定國家認可委員會(“CNAS”)授予的實驗室認可證書及認可決定書(註冊號:CNASL12178)的基礎上,於近日通過了CNAS定期監督評審,同時新增了血細胞、白細胞、血紅蛋白、紅細胞比容、血小板項目擴項認可,至此公司參考實驗室共獲得酶學、蛋白、小分子代謝物、血細胞等四大領域共15個項目的認可,生效日期為2020年9月9日,有效期至2025年04月21日。公司參考實驗室首次獲得證書日期為2019年4月22日。

CNAS是根據《中華人民共和國認證認可條例》的規定,由國家認證認可監督管理委員會(CNCA)批准設立並授權的國家認可機構,統一負責對認證機構、實驗室和檢驗機構等相關機構的認可工作。CNAS是國際認可論壇(IAF)、國際實驗室認可合作組織(ILAC)、亞太實驗室認可合作組織(APLAC)和太平洋認可合作組織(PAC)的正式成員(2019年1月1日起,PAC和APLAC合併成立新的區域認可合作組織“亞太認可合作組織”(APAC)。CNAS認可已經融入國際認可互認體系,在國際認可活動中佔據重要地位。

公司此次新增血細胞相關CNAS參考實驗室認可資格,將進一步擴展公司實驗室的研究種類,使公司的資質及技術、管理水平得到了進一步的確認,有助於提升公司產品的公信力及品牌影響力,增強公司在行業內的核心競爭力,但其對未來收入的貢獻程度尚不能預計。敬請投資者注意投資風險。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account